HIV-1 Broadly Neutralizing Antibodies: Identification, Development and Vaccine EvaluationZaibao Zhang1,2*, Qian Guan3and Hongyu Yuan1,2
- *Corresponding Author:
- Zaibao Zhang
Institute for Conservation and Utilization of Agro-bioresources in Dabie Mountains
Xinyang, Henan, China
Tel: +86 13826272603
E-mail: [email protected]
Received date: November 02, 2016; Accepted date: November 12, 2016; Published date: November 19, 2016
Citation: Zhang Z, Guan Q, Yuan H (2016) HIV-1 Broadly Neutralizing Antibodies: Identification, Development and Vaccine Evaluation. J AIDS Clin Res 7:636. doi:10.4172/2155-6113.1000636
Copyright: © 2016 Zhang Z, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Numerous human immunodeficiency virus-1 (HIV-1) broadly neutralizing antibodies (bNAbs) have been produced and details of their generation, evolution and structure provide a blueprint for effective vaccination. Recent advances in next generation sequencing (NGS) technologies have allowed high-resolution characterization of the antibody repertoire, and have enabled thorough characterization of many HIV-1 bNAbs. These bNAbs identified conserved epitopes that may be used to design new vaccines and provided new tools for prophylaxis and therapy for HIV- 1 disease. In this review, we summarize the advance in HIV-1 bNAbs discovery, maturation and further describe emerging applications in vaccine design.